secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001628280-26-028854
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira Q1 revenue $177M (+5% YoY); GAAP EPS $0.07, non-GAAP $0.60; FY guidance reiterated
--------------------------------------------------------------------------------

- Total revenue $177.4M (+5% YoY); EXPAREL $143.3M (+5%), ZILRETTA $26.8M (+15%), iovera° $6.2M (+21%).
- GAAP net income $2.9M ($0.07/diluted); non-GAAP net income $24.5M ($0.60/diluted); adjusted EBITDA $40.2M.
- Repurchased 2.2M shares for $50M at avg $22.28; $100M remains under authorization through Dec 2026.
- Completed ZILRETTA Phase 3 enrollment for shoulder OA; topline readout expected by end of 2026.
- Reiterated FY 2026 guidance: EXPAREL $600-620M, total revenue $745-770M, non-GAAP gross margin 77-79%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000162828026028854/0001628280-26-028854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000162828026028854/pcrx-20260430.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-028854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer